Online inquiry

IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15880MR)

This product GTTS-WQ15880MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SLC34A2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001300868.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3177
UniProt ID Q14542
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15880MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5764MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ12450MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ5180MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
GTTS-WQ8705MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ15920MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ3775MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ2112MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ13528MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW